Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on May 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on April 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 5/1/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 5/1/2026.
• Sold $1,001 – $15,000 in shares of SS&C Technologies (NASDAQ:SSNC) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Wayfair (NYSE:W) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of STERIS (NYSE:STE) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Sensata Technologies (NYSE:ST) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Veralto (NYSE:VLTO) on 5/1/2026.

BridgeBio Pharma Price Performance

BBIO traded up $0.48 during trading on Tuesday, hitting $65.16. 353,861 shares of the stock traded hands, compared to its average volume of 2,756,525. The firm has a market capitalization of $12.76 billion, a P/E ratio of -17.42 and a beta of 1.02. BridgeBio Pharma, Inc. has a 12-month low of $31.77 and a 12-month high of $84.94. The firm has a 50-day moving average of $71.23 and a 200 day moving average of $71.47.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.14). The business had revenue of $194.52 million for the quarter, compared to analysts’ expectations of $178.07 million. The company’s revenue for the quarter was up 66.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.88) EPS. As a group, equities analysts predict that BridgeBio Pharma, Inc. will post -2.05 EPS for the current fiscal year.

BridgeBio Pharma News Roundup

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: BridgeBio submitted an NDA to the FDA for encaleret in ADH1 after reporting strong Phase 3 CALIBRATE data, a potentially important regulatory step that could expand the company’s commercial pipeline. Article: BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
• Positive Sentiment: HC Wainwright raised its earnings estimates for BridgeBio’s Q2, Q3 and Q4 2027 periods and kept a Buy rating with a $110 price target, reinforcing a bullish long-term view. Article: BridgeBio Pharma Price Target Raised to $110.00 at HC Wainwright
• Positive Sentiment: HC Wainwright also boosted its Q4 2027 EPS estimate, suggesting improved confidence in BridgeBio’s future profitability. Article: HC Wainwright Q4 2027 EPS estimate increase
• Positive Sentiment: The company’s acoramidis update showed continued disease-modifying effects in ATTR-CM, including reduced heart-failure worsening events, which supports the drug’s commercial thesis and investor confidence. Article: Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
• Positive Sentiment: BridgeBio announced a $500 million stock repurchase program, which can be seen as a signal of management confidence and a potential source of share-price support. Article: BridgeBio Pharma Announces $500 Million Stock Repurchase Program
• Neutral Sentiment: Analysts have been updating estimates after BridgeBio’s first-quarter results, indicating continued attention to the company’s outlook, but not a clear immediate catalyst on its own. Article: Analysts Are Updating Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Estimates After Its First-Quarter Results
• Negative Sentiment: CEO Neil Kumar sold 40,000 shares in a pre-arranged 10b5-1 transaction, which can still weigh on sentiment even if it was planned in advance. Article: SEC Form 4 insider sale by Neil Kumar

Insider Transactions at BridgeBio Pharma

In related news, CEO Neil Kumar sold 40,000 shares of the stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $67.90, for a total transaction of $2,716,000.00. Following the sale, the chief executive officer directly owned 575,686 shares of the company’s stock, valued at approximately $39,089,079.40. This represents a 6.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Randal W. Scott sold 10,000 shares of BridgeBio Pharma stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $75.46, for a total transaction of $754,600.00. Following the completion of the transaction, the director directly owned 11,589 shares of the company’s stock, valued at $874,505.94. This trade represents a 46.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 239,084 shares of company stock valued at $16,615,979. 14.23% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BBIO. Global Retirement Partners LLC boosted its stake in BridgeBio Pharma by 271.5% during the fourth quarter. Global Retirement Partners LLC now owns 509 shares of the company’s stock worth $39,000 after acquiring an additional 372 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of BridgeBio Pharma by 91.4% in the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock worth $39,000 after purchasing an additional 245 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of BridgeBio Pharma in the 4th quarter worth approximately $41,000. Cary Street Partners Investment Advisory LLC increased its position in BridgeBio Pharma by 861.0% during the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 567 shares of the company’s stock valued at $43,000 after buying an additional 508 shares in the last quarter. Finally, Eurizon Capital SGR S.p.A. purchased a new position in BridgeBio Pharma during the fourth quarter valued at $44,000. 99.85% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Mizuho reiterated an “outperform” rating and issued a $106.00 price objective on shares of BridgeBio Pharma in a report on Tuesday, April 28th. HC Wainwright raised their price target on BridgeBio Pharma from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday. TD Cowen reiterated a “buy” rating on shares of BridgeBio Pharma in a report on Monday, January 12th. Truist Financial upped their price objective on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Finally, JPMorgan Chase & Co. raised their target price on shares of BridgeBio Pharma from $89.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 10th. Twenty-four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $88.19.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.